Mirum Pharmaceuticals, Inc. (MIRM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Mirum Pharmaceuticals, Inc. (MIRM) closed at USD 79.96 on 2026-10-14, a change of +13.4 % over the past year, with a market capitalization of USD 5.35B.

Mirum Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Mirum Pharmaceuticals, Inc. key figures

Previous close

USD 79.96 (2026-10-14)

1-year change

+13.4 %

Market cap

USD 5.35B

Enterprise value

USD 5.67B

P/E ratio (trailing)

-5.65

P/E ratio (forward)

-114.43

EPS (trailing)

-14.59

EPS (forward)

-0.72

PEG ratio

n/a

Price to book

-511.74

Revenue growth

37.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.65

Employees

433

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Mirum Pharmaceuticals, Inc. and compare it with other stocks.